Recent studies of rhabdomyosarcoma have concluded that combined inhibition of MEK and mTOR is synergic because of anti-counteractive interaction: each drug blocks reciprocal activation of the other pathway (31,32). This evidence concerns the gene MAP2K7 and rhabdomyosarcoma.